Abstract: 5-HT 1A autoreceptor antagonists enhance the effects of antidepressants by preventing a negative feedback of serotonin (5-HT) at somatodendritic level. The maximal elevations of extracellularconcentration of 5-HT (5HText) induced by the 5-HT uptake inhibitor paroxetine in forebrain were potentiated by the 5-HT1A antagonist WAY-100635 (1 mg/kg s.c.) in a regionally dependent manner (striatum > frontal cortex > dorsal hippocampus). Paroxetine (3 mg/kg s.c.) decreased forebrain 5-Hlext during local blockade of uptake. This reduction was greater in striatum and frontal cortex than in dorsal hippocampus and was counteracted by the local and systemic administration of WAY-100635. The perfusion of 50 pmol/L citalopram in the dorsal or median raphe nucleus reduced 5HText in frontal cortex or dorsal hippocampus to 40 and 65% of baseline, respectively. The reduction of cortical 5HText induced by perfusion of citalopram in midbrain raphe was fully reversed by WAY-100635 (1 mg/kg s.c.). Together, these data suggest that dorsal raphe neurons projecting to striatum and frontal cortex are more sensitive to self-inhibition mediated by 5-HT1A autoreceptors than median raphe neurons projecting to the hippocampus. Therefore, potentiation by 5-HT1A antagonists occurs preferentially in forebrain areas innervated by serotonergic neurons of the dorsal raphe nucleus. Key Words: 5-HT1A receptor antagonist-5-Hydroxytryptamine (serotonin) -5-Hydroxytryptamine uptake inhibitors-Dorsal raphe nucleus-Median raphe nucleus-Paroxetine.
The treatment of major depression with selective serotonin F 5-hydroxytryptamine (5-HT)] reuptake inhibitors (SSRIs) is effective in less than two-thirds of patients. SSRIs selectively block the 5-HT transporter (Hyttel, 1994) , and therefore their clinical actions likely derive from an enhancement of serotonergic transmission. Yet, clinical improvement requires prolonged treatments despite the capacity of SSRIs to block the 5-HT transporter rapidly. Neurochemical studies have shown that 5-HT uptake inhibitors increase the extracellular concentration of 5-HT (5-HText) in the midbrain raphe nuclei (Adell and Artigas, 1991; Fuller, 1994; Gardier et al., 1996) , which constitute the main source of forebrain serotonergic innervation (Dahlström and Fuxe, 1964) . The excess 5-HT~~1 in the midbrain raphe activates somatodendritic autoreceptors and reduces 5-HT release in forebrain (Adell and Artigas, 1991; Rutter and Auerbach, 1993; Romero et al., 1994) . As a result, single treatment with clinically relevant doses of SSRIs causes little or no increase of 5-HT~~ĩn forebrain (Bel and Artigas, 1992; Invernizzi et al., 1992; Gartside et al., 1995; Malagié et al., 1996) . Because the forebrain 5-HT release depends on nerve impulse, these observations are consistent with the suppression of firing evoked by antidepressants in 5-HT neurons of the dorsal raphe nucleus (Aghajanian et al., 1970; Scuvée-Moreau and Dresse, 1979; Blier and de Montigny, 1994) .
It was thus hypothesized that addition of 5-HT A antagonists could enhance the antidepressant effects of SSRIs by preventing this negative feedback (Artigas, 1993) . Two pilot studies using pindolol (a nonselective~-adrenoceptor/5-HTlA antagonist) have reported results consistent with this hypothesis (Artigas et al., 1994a; Blier and Bergeron, 1995) , which has received further confirmation in a controlled trial (V. Pérez et al., manuscript in preparation). (-)-Pïndolol prevents the self-inhibition of dorsal raphe serotonergic neurons produced by the SSRIs and therefore potentiates their effects in various brain areas (Artigas et al., 1994b; Dreshfield et al., 1996; Romero et al., 1996) . Serotonergic neurons of the dorsal and median raphe nuclei innervate different forebrain territories (Azmitia and Segal, 1978) . The activation of 5-HTtA autoreceptors by selective agonists has been reported to cause a greater reduction of activity in 5-HT neurons of the dorsal raphe nucleus (Sinton and Fallon, 1988; Blier et al., 1990 ) and of 5-HT synthesis and release from the corresponding axon terminals (Invernizzi et al., 1991; Casanovas and Artigas, 1996) . However, such a differential sensitivity has not been found by others (Hjorth and Sharp, 1991; Hajos et al., 1995) , and therefore it is not firmly established whether 5-HT release is equally inhibited by SSRIs in dorsal and median raphe tracts. Using microdialysis in awake rats, we have assessed the role of somatodendritic 5-HT 1 A autoreceptors in the potentiation of SSRI effects by 5-HTIA antagonists and the putative differential sensitivity of dorsal and median raphe neurons to self-inhibition after treatments with SSRIs.
MATERIALS AND METHODS

Animals
Male Wistar rats (Iffa Credo, Lyon, France) weighing 280-320 g were used. Animals were kept in a controlled environment (12-h light-dark cycle and 22 ± 2°C room temperature). Food and water were provided ad libitum. Animal care followed the European Union regulations (O.J. of E.C. L358/l 18/12/1986).
Drugs and reagents
5-HT was from Research Biochemicals International (Natick, MA, U.S.A.). The SSRIs citalopram HBr and paroxetine HCI were generously provided by Lundbeck and Smith Kline Beecham, respectively. WAY-l00135 { (S)-N-tertbutyl -3-[4-(2-methoxyphenyl )piperazin -I -yl I -2-phenylpropanamide } (Cliffe et al., 1993) (Fletcher et al., 1995) , and [ 3H]WAY-100635 (specific activity, 80 Ci/mmol) were generously supplied by Wyeth Ayerst. Other materials and reagents were from local commercial sources. Drugs were injected intraperitoneally or subcutaneously at the doses indicated (base form; 1-2 mI/kg) or dissolved in the microdialysis perfusion fluid for local applications by reverse dialysis. Neither citalopram nor WAY-l00635 altered substantially the pH of the artificial CSF used to perfuse the probes.
Microdialysis experiments
Four different sets of experiments were performed to examine the role of somatodendritic 5-HT A autoreceptors in the control of 5-HT release during the local or systemic treatment with SSRIs. First, the effects of paroxetine, alone or in combination with WAY-100635 (1 mg/kg, s.c.), on 5-HT~X were examined in four forebrain areas (striatum, frontal cortex, ventral hippocampus, and dorsal hippocampus) differentially innervated by serotonergic neurons of the dorsal and median raphe nuclei (Azmitia and Segal, 1978) .
Animals were randomly allocated to receive either paroxetinc plus saline or paroxetine plus WAY-100635. Second, WAY-100635 (100~imol/L) was administered through 1.5-mm-long probes located in the dorsal raphe nucleus (Ferré et al., 1994) during the systemic treatment with paroxetine to examine the involvement of sornatodendritic 5-HT 1,~aut-oreceptors. Pilot experiments revealed that lower concentrations ofWAY-100635 (I and 10~imol/L) did not attenuate the reduction of cortical 5-HT release induced by application of citalopram in the dorsal raphe nucleus. A third group of experiments was performed, based on the observation that the systemic administration of an SSRI resulted in a reduction of 5-HT release in the dicncephalon and hippocampus when the 5-HT transporter was blocked in these areas by the local infusion of a SSRI using reverse dialysis (Rutter and Auerbach, 1993; Hjorth and Auerbach. 1994) . This reduction results from the activation of somatodendritic 5-HTIA autoreceptors by the excess 5-HT~ĩn the interstitial space outside the cell bodies produced by 5-HT uptake blockers (Adell and Artigas, 1991: Bel and Invernizzi et al., 1992; Gartside et al., 1995; Malagié et al., 1996 ). WAY-100635 was then locally (in the dorsal raphe nucleus) or systemically administered to examine its effects on 5-HTCS~in frontal cortex. Animals were randomly implanted with probes in striatum and dorsal hippocampus. Finally, the fourth set of experiments included the local activation of somatodendritic 5-HT1,5 receptors in the dorsal or median raphe nucleus [using 1.5-mm-long probes (Ferré et al., 1994) ] or in the dorsal plus median raphe nuclei [using 4-mm-long probes, 0.5 mm away from the midline (Adell and Artigas, 199lfl by the local application of the SSRI citalopram in rats with dual probe implants (dorsal raphestriatum; median raphe-dorsal hippocampus). The blockade of the 5-HT uptake increases 5-HT~~5 in the midbrain raphe and reduces 5-HT release in frontal cortex (Adell and Artigas, 1991) and striatum (Romero et al., 1994 (Romero et al., , 1996 . 5-HTA antagonists were then systemically administered to assess their effects on the reduction of terminal 5-HT release induced by citalopram. Anesthetized rats (pentobarbital, 60 mg/kg i.p.) were implanted stereotaxically with 0.25-mm-od., concentric dialysis probes (Adell and Artigas, 1991) in the different brain areas (Table I) . Microdialysis experiments were conducted -20 h after probe implants in conscious, freely moving animals. Animals were implanted with one or two microdialysis probes in the regions of interest, as required by the experimental model used. In one experiment, citalopram was infused into the dorsal raphe nucleus through a metal tube at 0.05~zl/min (Romero et al., 1994) instead of being delivered by reverse dialysis. Both procedures induced equivalent reductions of 5-HT release in striaturn or frontal cortex.
Probes were perfused with artificial CSF (125 mM NaCI, 2.5 mM KCI, 1.26mM CaC12, and 1.18mM MgCL) at 0.25 d/min. Under these conditions, the in vitro recovery of the dialysis probes for 5-HT was 27 ± 2 (1.5 mm) and 42 ± 1% (4 mm). Sample collection started 60 min after the beginning of perfusion. Usually four or five fractions were collected to obtain basal values before either local infusion or systemic administration of drugs. Successive 20-min dialysate samples were collected. Because of the marked reduction of cortical and striatal 5-HT release elicited by the local infusion of citalopram in the somatodendritic area (Romero et al., 1994 (Romero et al., , 1996 , probes of the animals of the fourth experimental group were perfused with artificial CSF containing 1~smol/L citalopram. This enhanced the detectability of 5-HT and reduced the variability of the measures without affecting the experimental model, i.e., control of terminal release through the activation of somatodendritic 5-HT1,5 by 5-HT. Similarly, cortical probes of the animals of the third Coot'dinates (AP, DV, and L) are given in mm, with respect to bregma and dura mater according to the rat brain atlas of Paxinos and Watson (1986) .
"The dorsoventral coordinate corresponds to the actual descent of the probe along a line inclined 13 or 30°with respecl to the vertical.
group were perfused with 1 pmol/L citalopram, as required in this experimental model (Rutter and Auerbach, 1993; I ljorth and Auerbach, 1994) .
Chromatographic analysis
5-HT was analyzed by a modification of an HPLC method previouslydescribed (Adell and Artigas, 1991) . The composition of HPLC eluant was as follows: 0.15 M NaH 2PO4, 1.3 mM octyl sodium sulfate, 0.2 mM EDTA (pH 2.8 adjusted with phosphoric acid), pILls 27% methanol. 5-HT was separated on a 3-pm (particle size) ODS 2 column (7.5 >< 0.46 cm; Beckman) and detected amperometrically with a Hewlett Packard model 1049 detector (oxidation potential, f t).6 V). Retention time was 3.5-4 min. The detection Inuit l'or 5-HT was 0.5-l fmol.
In vivo labeling of 5-HTIA receptors by
I~H I WAY-100635
The extent of the diffusion of WAY-100635 in the midbrain raphe area after its local application in the dorsal raphe nucleus by reverse dialysis was determined using I il lj WAY-I 00635. Dialysis probes (1.5 mm long) were placed in the dorsal raphe nucleus and perfused (0.25 p1/ miii) with artilicial CSF containing 100 pmol/L WAY-100635 (plus 100 nmol/L radioactive tracer). The in vitro recovery of the dialysis probes (1.5 mm) for WAY-100635 was calculated from the radioactivity counts in equivalent volitmes of the artificial CSF at the probe inlet and outlet during the infusion of flHjWAY-100635 plus WAY-100635. This was found to he 58.7 ± 4.6% (n = 4). After nit inILtsion period of 1.2 h. the rats were decapitated, and lic brains wei~eremoved and frozen. Coronal midbrain sections (14 pm thick) were cut to examine the in vivo labeling ni dorsal raphe nucleus 5-HTIA receptors by [ 3HiWAY-1)0635 (Laporte et al., 1994; Gozlan et al., 1995; Khawajaet tI., 1995) . Given the rostrocaudal distribution of the various neuronal groups composing the dorsal raphe nucleus, coronal sections were cut at different anteroposterior levels (approxiittately froin -6.5 to --9.0mm relative to bregma). Sections :tt hippocampal and cortical levels were also cut to examine whether 5-HTIA receptors in these areas (Marcinkiewicz et aI.. 1984; Pazos and Palacios, 1985; Pompeiano et al., 1992) were also labeled by infusion of [3H]WAY-100635. The scclions were exposed to a tritium-sensitive film (Hyperfilm-'li; Aniershani, U.K.) for 3 weeks. The optical density of lIte tritium labeling in films was measured using an image analysis system (Imaging Research, St. Catharines, Ontario, Canada). The surface of areas showing a dense labeling by [3H]WAY-l00635 was quantified to calculate the total amount of tritium label in each section.
Data analysis
Microdialysis results are expressed as femtomoles per fraction (uncorrected for recovery) and represented as percentages of basal values (individual means of four predrug fractions) to facilitate comparisons between the different experimental groups. Statistical analysis of single drug effects has been performed using ANOVA for repeated-measures and paired t tests of raw data. Two-way ANOVA designs were used to examine the interaction between 5-HT 1,5 antagonists and SSRIs or regional effects. ANOVA of areaunder-the-curve (AUC) data was also used to examine the dose and region factors on dialysate 5-HT after the treatment with paroxetine. Autoradiographic data are expressed as femtomoles of [ 3H]WAY-100635 per section. Data are given as mean ±SEM values. Statistical significance has been set at the 95% confidence level (two tailed).
RESULTS
Increase of 5-HT~~1
in forebrain by paroxetine Table 2 shows the basal values of dialysate 5-HT (with and without I~.tmol/L citalopram in the perfusion fluid) in the different brain regions examined. The intraperitoneal administration of 3 mg/kg paroxetine significantly increased dialysate 5-HT levels in four forebrain areas differentially innervated by the dorsal and median raphe nuclei (striatum, frontal cortex, ventral hippocampus, and dorsal hippocampus) (p <0.001 by repeated-measures ANOVA). Minimal and maximal elevations of dialysate 5-HT in the different regions were 231 and 289% of basal values (AUCs of 160 min postparoxetine) in dorsal hippocampus and striatum, respectively (Fig. 1) . These elevations were not significantly different (one-way ANOVA). The increment of the paroxetine dose to 10 mg/kg did not elevate further dialysate 5-HT levels in frontal cortex (p < 0.001 for effect of paroxetine treatment; nonsignificant effect of the dose by two-way ANOVA). By contrast, 10 mg/kg elicited a somewhat larger increment of 5-HT001 in ventral hippocampus, which was significantly different from that produced by 3 mg/kg, particularly at short times after paroxetine administration (p < 0.001, significant effects of the treatment and the dose factors; Fig. 2 ).
Potentiation of paroxetine effects on 5-HT~~1 by WAY-100635
The systemic administration of WAY-100635 (I mg/ kg s.c.) to saline-pretreated rats did not modify 5-HT~01 in frontal cortex, striatum, or dorsal hippocampus (AN-OVA for repeated measures) (Fig. 3) . However, its administration caused dramatic elevations of 5-HT00 in the striatum and frontal cortex of rats pretreated with 3 mg/kg i.p. paroxetine ( Fig. 3; to almost 1,800% in the striatum. The effect in dorsal hippocampus was less marked (see Fig. 3, lower panel) . The maximal potentiation of paroxetine effects was noted 40 min after administration of WAY-l00635 in all brain areas. A two-way ANOVA of the AUC values during the period of maximal potentiation (four fractions) after the injection of WAY-100635 or saline revealed significant effects of the treatment and region factors (p < 0.001 in both cases) and a significant interaction (p < 0.027) of both factors.
To assess the participation of somatodendritic 5-HTIA receptors in the potentiation of the paroxetineinduced 5-HT elevations after the systemic treatment with WAY-l00635, we examined the effects of its local application in the dorsal raphe nucleus (100 imol/L for 160 min at 0.25 ‚uI/mm; total amount delivered was 2.35 nmol taking into account the yield of the dialysis membrane; 14.7 pmol/min) during the administration of paroxetine. The infusion of WAY-100635 in the dorsal raphe nucleus rapidly and significantly increased dialysate 5-HT values in frontal cortex of rats pretreated with 3 mg/kg paroxetine and remained elevated for the rest of the infusion period (p <0.01 vs. paroxetine alone by Student' s t test of AUCs during perfusion time; p < 0.004 by repeated-measures ANOVA vs. pre-WAY-100635 value; Fig. 4) .
Actions of 5-HT at dorsal and median raphe 5-HT1A receptors: Antagonism by WAY-100635
Somatodendritic 5-HT A receptors were activated by 5-HT after the local or systemic administration of the We further assessed the ability of paroxetine to reduce 5-HT in dialysates from dorsal striatum and dorsal hippocampus, two areas innervated in a preferential manner by serotonergic axons originating in the dorsal and median raphe nucleus, respectively. To exclude any methodological source of possible differences, the size of the microdialysis probes was the same (1.5 mm) in dorsal hippocampus and striaturn. The administration of 3 mg/kg paroxetine significantly reduced 5-HT content in both areas, although to a greater extent in the striatum (p < 0.0001, significant effect of the treatment; p < 0.0001, significant treatment X region interaction; Fig. 5, lower panel) . The reduction of 5-HT release was counteracted by systemic administrationof 1 mg/kg WAY-100635 (p <0.001 by repeatedmeasures ANOVA) in both regions. WAY-100635 caused 5-HT values to increase above pretreatment levels. This is likely due to additional blockade of the Table 1 transporter by the systemic administration of paroxetinc plus the prevention of the self-inhibition by WAY-100635.
In a second set of experiments, citalopram (50 pmol/L) was infused through 1.5-mm dialysis probes in the dorsal or median raphe of animals implanted with a second probe in frontal cortex or dorsal hippocampus, respectively. Application of citalopram in the dorsal raphe nucleus caused a rapid and sustained elevation of dialysate 5-HT, which was followed by a very marked reduction of the 5-HT output in frontal cortex (p < 0.001 for both regions by repeated-measures ANOVA; Fig. 6) . Similarly, the application of the same citalopram concentration in the median raphe nucleus caused a very large increase in 5-HT content (maximal increase to 15-fold of baseline) that was also accompanied by a reduction of the 5-HT output in dorsal hippocampus (p < 0.001 for both regions by repeated-measures ANOVA; Fig. 6, lower panel) . A two-way analysis of the data also revealed a significant treatment X region interaction (p < 0.001).
When citalopram was infused through a vertical probe (4 mm long, 0.5 mm away from the midline) in the vicinity of both midbrain raphe nuclei, a somewhat smaller but still very marked enhancement of dialysate 5-HT in the midbrain was observed (p < 0.001 by repeated-measures ANOVA; Fig. 7, upper panel) . This was accompanied by a decline of dialysate 5-HT values in frontal cortex to 55% of basal levels (p < 0.001; Fig. 7, lower panel) Fig. 7 ). The blockade of 5-HT A receptors by WAY-100635 was reversible, as 2 h after its administration cortical and raphe dialysate 5-HT values had almost returned to pre-WAY-l00635 values, while citalopram was still being infused in the midbrain raphe.
The infusion of 50 ‚umol/L citalopram in the dorsal raphe nucleus caused a marked reduction of striatal 5-HT release that was not counteracted by the 5-HTIA antagonist WAY-100l35 at 10 mg/kg (significant effects of citalopram, p < 0.001 in both cases; nonsignificant effect of the pretreatment with WAY-100135; Fig. 8 ).
Autoradiographic analysis of distribution of [ 3H]WAY-100635 in rat brain after local application in dorsal raphe nucleus
To examine the involvement of somatodendritic and postsynaptic 5-HT A receptors in the action of locally applied WAY-100635, we perfused 100 pmol/L WAY-100635 plus 100 nmol/L [3H]WAY-100635 into the dorsal raphe nucleus, using the same experimental conditions as in previous microdialysis experiments, except for the infusion time, which was reduced to half (1 h 20 mm). At this time, WAY-l00635 had already exerted its full antagonistic effects (see Figs. Arrow denotes the subcutaneous injection of saline (U) or 10 mg/kg WAY-i 00135 (7). Two-way ANOVA did not reveal a significant effect of Data are mean ± SEM (bars) values from six or seven rats. For comparison, the antagonistic effects of 15 mg/kg (-)-pmndolol using the same experimental procedure are shown (dotted line). Data for pindolol are from Romero et al. (1996) . 4 and 5), and therefore the infusion for additional time was not considered necessary, thus helping to minimize the amount of radioactivity used. Autoradiographic analysis showed that the radioactive label was distributed along the anteroposterior axis at the dorsal raphe level, with greater amounts in central regions (Fig. 9) . Neither the neighbor median raphe nucleus nor more distant areas rich in postsynaptic 5-HT A receptors, like the hippocampus or frontal cortex, showed any sign of labeling by [ 3H]WAY-100635 (Fig. 10) .
DISCUSSION
The serotonergic system is involved in many brain functions, such as motor control, cognition, process of sensory information, and mood regulation (Jacobs and Azmitia, 1992; Jacobs and Fornal, 1993; Maes and Meltzer, 1995) . A relatively small number of cells in the midbrain raphe nuclei innervates all forebrain areas with a very high density of nerve terminals (Descarries et al., 1982; Oleskevich and Descarries, 1990; Jacobs and Azmitia, 1992) . Serotonergic neurons are extremely sensitive to self-inhibition by 5-HT (Aghajanian et al., 1972; Haigler and Aghajanian, 1974) . This process is mediated by somatodendritic S-HT IA receptors coupled through G 1/G0 proteins to a K~channel (Aghajanian and Lakoski, 1984; Blier and de Montigny, 1987; Sprouse and Aghajanian, 1987; Innis et al., 1988) . Consequently, the activation of somatodendritic S-HT IA receptors results in a widespread reduction of the electric and metabolic activity in ascending serotonergic axons.
The SSRIs act as indirect S-HT IA agonists owing to the excess S~HText produced by these agents in the midbrain raphe. This activates somatodendritic S-HT IA autoreceptors and limits the increment of SHText produced in forebrain. The present results indicate that the maximal effects of the systemic administration of paroxetine, a very potent SSRI (Thomas et al., 1987; Hyttel, 1994) , in various forebrain regions are limited to a two-to threefold increment of S~HTex1(see, however, the large increment of S~HTextproduced in forebrain by the partial local blockade of the S-HT transporter by 1 ‚umol/L citalopram in Table 2 ). Yet, the subsequent administration of WAY-100635, a very selective and potent S-HTIA antagonist (Fletcher et al., 1995; Forster et al., 1995) counteracted the self-inhibition produced by paroxetine and markedly potentiated the increase of S-HT~0~. In keeping with the present results, several groups have reported the potentiation of SSRI-induced forebrain increases of S-HT~01by selective and nonselective S-HTIA antagonists (Invernizzi et al., 1992 (Invernizzi et al., , 1996 Hjorth, 1993; Artigas et al., 1994b; Gartside et al., 1995; Arborelius et aI., 1996; Dreshfleld et al., 1996; Romero et al., 1996) . This effect is likely mediated at somatodendritic level, as the intraraphe or systemic application of 5-HT IA antagonists prevented the inhibition of cell firing and terminal S-HT release elicited by the activation of somatodendritic S-HT IA receptors (Blier and de Montigny, 1994; Arborelius et al., 1995; Gartside et aI., 1995; Romero et al., 1996; see also Fig. S) .
Anatomical data indicate that the striatum and the frontal cortex are innervated by 5-HT neurons of the dorsal raphe nucleus in an exclusive and preferential manner, respectively (Azmitia and Segal, 1978; 1mai et al., 1986) . In contrast, the dorsal hippocampus is mostly innervated by S-HT neurons of the median raphe nucleus. The preferential enhancement of S~HText by WAY-l0063S in striatum and frontal cortex agrees with previous data indicating a greater inhibition of the activity of serotonergic neurons of the dorsal raphe nucleus after systemic treatment with S-HTIA agonists (Sinton and Fallon, 1988; Blier et al., 1990; Invernizzi et al., 1991; Lésourd et al., 1995; Casanovas and Artigas, 1996) . It is unclear whether this is due to a differ- ential reduction of cell firing at the cell body level by these agents or whether local factors in projection areas are involved, as recent data suggest an equal potency of paroxetine to inhibit dorsal raphe and median raphe neurons in anesthetized rats . The present observations indicate that the 5-HT release by axon terminals of dorsal raphe neurons of the corticostriatal pathway is inhibited to a greater extent than that in the median raphe-hippocampal tract. This is supported by two different sets of experiments in which 5-HT A receptors in the dorsal or median raphe nucleus have been locally or systemically activated by 5-HT and is in full agreement with the greater potentiation of paroxetine effects by WAY-100635 in striatum and frontal cortex (as compared with dorsal hippocampus).
The synergistic action of WAY-I 00635 most likely results from the blockade of S-HTIA receptors, as it prevents the suppression of cell firing induced by 8-hydroxy-2-(di-n -propylamino) tetralin (Forster et al., 1995) . Serotonergic neurons of the dorsal raphe nucleus also express 5-HTIB and 5-HTI) subtypes (for review, see Hoyer et al., 1994) , and 5-HT 10 receptors may also behave as somatodendritic autoreceptors (Pifleyro et al., 1995) . However, the affinity of WAY-100635 for 5-HTIB/ID receptors is much lower than that for the 5-HT!A receptors (Forster et al., 1995) , and the cell firing of serotonergic neurons is not controlled by 5-HT10 receptors Aghajanian, 1987, 1988) . These observations argue against the involvement of other 5-HT receptor subtypes in the 5-HT-enhancing action of WAY-100635.
The infusion of citaloprarn in the dorsal raphe nucleus or in the vicinity of dorsal and median raphe nuclei caused a marked reduction of 5-HT release in frontal cortex, likely resulting from the activation of somatodendritic 5-HTIA autoreceptors, as the systemic administration of WAY-l00635 fully reversed the cortical 5~HTexdecline and further increased the citalopram-induced elevation of 5-HT00 in the raphe. The latter observation clearly indicates that 5-HT release in the dorsal and median raphe nuclei is also inhibited by activation of somatodendritic 5-HT JA receptors during the treatment with SSRls. lt is unclear whether there is a tonic inhibition of somatodendritic 5-HT release in a physiological situation in the rat brain, because WAY-I00635 did not elevate 5-HT005 in forebrain when administered alone. However, it moder-ately increased the firing rate of single units in the dorsal raphe nucleus of the awake cat (Fornal et al., 1996) , thus suggesting a tonic control of serotonergic cell firing by 5-HTtA receptors in this species during periods of behavioral activation. The absence of a corresponding increment in the forebrain S-HT release in rats may possibly be related to changes in the S-HT A tone across the sleep-waking cycle, as the present experiments were conducted during the period of low behavioral activity, i.e., daytime.
The local application of WAY-100635 in the dorsal raphe nucleus potentiated the systemic effects of paroxetine in frontal cortex and partially counteracted the reduction of cortical S-HT release induced by systemic paroxetine when the 5-HT uptake was locally blocked in frontal cortex. The conspicuous and selective labeling of the dorsal raphe nucleus by~3 H]WAY-l0063S when locally infused indicated that only somatodendritic S-HT IA receptors of this nucleus were involved. However, WAY-10063S seemed to be more effective at antagonizing the inhibitory effects of 5-HT at 5-HTIA receptors after its systemic administration, which may indicate either the involvement of postsynaptic S-HTtA receptors in this effect or a more effective antagonism after systemic administration. Indeed, the activity of dorsal raphe neurons is controlled by forebrain afferents (Kalén and Wiklund, 1989; Kalén et al., 1989; Behzadi et al., 1990; Levine and Jacobs, 1992; Peyron, 1996) , and it has been suggested that postsynaptic S-HT IA receptors may participate in the reduction of the activity of dorsal raphe nucleus serotonergic neurons by 5-HTIA agonists (Blier and de Montigny, 1987; Ceci et al., 1994; Romero et al., 1994) . Likewise, the hippocampal application of 5-HT IA agonists reduced dorsal raphe nucleus neuronal firing, but this effect may be perhaps mediated by diffusion via CSF (Jolas et al., 1995) . The present data fully support that somatodendritic S-HT IA receptors participate in the potentiation of paroxetine effects by WAY-10063S but cannot fully exclude the involvement of postsynaptic S-HT IA receptors.
WAY-100135 has been shown to prevent the reduction of terminal 5-HT release elicited by systemic administration of 8-hydroxy -2-(di -n -propylaminotetralin) or by moderate increments of 5~HText in the dorsal raphe nucleus Ferré et al., 1994; Hjorth and Auerbach, 1994) . However, in contrast to other mixed ß-adrenoceptor/S-HT A antagonists like (-)-tertatolol (Romero et aI., 1994) or (-)-pindolol (Romero et al., 1996) , WAY-100l35 did not prevent the reduction of striatal S-HT release induced by local application of citalopram in the dorsal raphe nucleus, a procedure causing a massive activation of S-HT IA autoreceptors by S-HT (see Figs. 6 and 7). The lesser ability of WAY-l00135 to antagonize self-inhibitory effects in the dorsal raphe nucleus suggests that this compound may be far less effective than its congener WAY-100635 in potentiating the actions of SSRIs. Also, WAY-100635 increased and WAY-100135 decreased S-HT cell firing in the awake cat (Fornal et aI., 1996) , a finding possibly related to the at-adrenolytic properties of the latter (Lanfumey et al., 1993) .
In summary, the present study supports the contention that selective 5-HT lA autoreceptor antagonists may augment the clinical effects of SSRIs by increasing serotonergic transmission more than the latter alone. This effect takes place preferentially in forebrain areas with selective or preferential innervation from the dorsal raphe nucleus, e.g., cortex and striatum, rather than those mainly innervated by the median raphe nucleus (dorsal hippocampus). These observations are important to clarify the relative role of serotonergic transmission in motor, limbic, and cortical areas during the recovery from depression. Also, the involvement of somatodendritic S-HT A receptors in the 5-HT-enhancing effects of S-HT IA antagonists has been extensively demonstrated. Thanks are given to Leticia Campa and Josefa Torres for their skillful technical assistance and to Teresa Abelldn, Roser Cortés, and J. M. Casanovas for help in some experiments. The Department of Neurochemistry is the recipient of grant I99SSGR-00445 from the CIRIT (Generalitat de Catalunya).
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